Avantor Makes Multi-Year Investment in Hydration Capabilities for Biologics Production
Avantor plans to address rising global demand for biologics with their investment in hydration capabilities.
Avantor announced a multi-year investment into its global hydration capabilities on Aug. 31, 2021 that includes a recently completed expansion to its facility in Gliwice, Poland, as well as a multi-stage expansion of its facility in Aurora, Ohio, that is expected to be completed by mid-2022.
The facility investments in Gliwice and Aurora will add to Avantor’s existing water for injection-quality (WFI) buffer manufacturing capabilities. The new equipment will provide enhanced capabilities and capacity to formulate and fill WFI-based hydration solutions, according to a company press release.
"Buffer management is a key area where biopharma manufacturers can save time while reducing risk and costs,” said Ger Brophy, executive vice-president of Biopharma Production at Avantor, in the press release. “This recent investment in our global hydration offering allows us to strengthen our [C]GMP [current good manufacturing practices] chemical manufacturing in Europe and the United States."
Source: Avantor
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
